Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
This is a descriptive, proof of concept, open-label, randomized, 3-arm, window of opportunity
trial to evaluate the immunomodulatory role of pharmacological ascorbate with Durvalumab